tirzepatide lily direct Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Eli Lilly launches website, home

Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine , 2022

Tirzepatide is a dual agonist that activates both the GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) receptors

A healthcare provider or registered dietitian may advise you on iron supplements if you need them

Another significant benefit of the medication class is its ability to reduce cardiovascular risk in patients with type 2 diabetes

In the quest for more effective treatments for diabetes, researchers have developed a groundbreaking solution that could revolutionize the way this chronic condition is managed